Eisai is pleased to announce that LENVIMATM (lenvatinib)is now approved for the treatment of locally…
Read More
Eisai is pleased to announce that LENVIMATM (lenvatinib)is now approved for the treatment of locally…
Revised label will facilitate use of Thyrogen to greater number of patients for postoperative thyroid…
Woodcliff Lake, NJ, February 2, 2014 – Eisai Inc. announced today that the Phase 3…
From the American Thyroid Association: In collaboration with the Food and Drug Administration (FDA), and…
AstraZeneca is pleased to announce two new clinical trials for patients with differentiated thyroid cancer….
Bayer and Onyx Pharmaceuticals Announce FDA Priority Review Designation of Nexavar® (sorafenib) Supplemental New Drug…
The ATA is pleased to confirm the launch of the ATA Corporate Information & Opportunities webpage which includes a link to the ATA corporate online news submission form.